Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln

Vertex Pharmaceuticals (VRTX.O) and its partner CRISPR Therapeutics (CRSP.BN) said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States. Bluebird bio (BLUE.O) said it has set a list price of $3.1 million for its treatment,…#crisprtherapeutics #blueo #lyfgenia
Source: Reuters: Health - Category: Consumer Health News Source Type: news